Third Rock Ventures One of Biotechs Daring Investors Raises $616M For More Startups
Oct 31, 2016, 11:52 AM
by
Michael Croft
Forbes | Biotech venture capital is supposed to be the highest-risk/highest-reward type of investment there is. But many biotech VCs are actually pretty conservative, hesitant to wager on edgy science that might take a decade to pay off. Not Third Rock Ventures.
October 31, 2016 | Biotech venture capital is supposed to be the highest-risk/highest-reward type of investment there is. But many biotech VCs are actually pretty conservative, hesitant to wager on edgy science that might take a decade to pay off. Not Third Rock Ventures. Forbes


